"IR(1): ≥50% increase in overall tumour burden (sum of the product of the perpendicular diameters (SPD) of up to six target measurable nodes and extranodal sites) occurred in the first 12 weeks of therapy and without clinical deterioration"
"IR(2): new lesions or ≥50% increase of existing lesion(s) without a ≥ 50% increase of overall tumour burden at any time during treatment."
"IR(3): increased FDG uptake of one or more lesions without any increase in size or number of those lesions"
"IR(2): new lesions or ≥50% increase of existing lesion(s) without a ≥ 50% increase of overall tumour burden at any time during treatment."
"IR(2): new lesions or ≥50% increase of existing lesion(s) without a ≥ 50% increase of overall tumour burden at any time during treatment."
"Indeterminate response (IR)"
Expected headings
"Indeterminate response (IR)"